Glycemic control outcomes of adults using the MiniMed™ 670G hybrid closed-loop (HCL) system: A single-center study.
MiniMed™ 670G hybrid closed-loop (HCL) insulin pump system offers Auto Mode basal insulin delivery based on patient's sensor glucose readings. The primary outcome of this study is to determine the correlation between Time in Auto Mode and Sensor Glucose Time in Range (SG-TIR) of 70-180 g/dL. Other secondary outcomes focusing on pump behavior characteristics were also assessed. A retrospective cohort study via chart review was conducted. Adult patients with either type 1 diabetes mellitus or Latent onset Diabetes in Adults (LADA) at an academic medical center endocrinology clinic who were switched to the MiniMed™ 670G HCL System either from multi-dose daily insulin injections (MDII) or another insulin pump with or without a continuous glucose monitor (CGM) were included. Pearson's Correlation Coefficient (r) was used to assess the correlation between variables in question within 9 months of switching. The level of statistical significance was set at α < 0.05. 12 patients with average baseline HbA1c of 8.2% (66 mmol/mol) were included. Time in Auto Mode correlated non-significantly but positively with SG-TIR (r = 0.478, p = 0.116). Positive correlations at various degrees were observed for secondary outcomes in question with a statistically significant reduction in HbA1c from baseline (-0.61%, CI 0.25-0.97) (-17 mmol/mol, CI 0.25-0.97) (p = 0.003). The MiniMed™ 670G HCL system Auto Mode functionality is beneficial for glycemic control in type 1 diabetes mellitus or LADA. The overall benefit may vary based on baseline characteristics such as HbA1c.